Literature DB >> 23524201

To sling or not to sling at time of abdominal sacrocolpopexy: a cost-effectiveness analysis.

Monica L Richardson1, Christopher S Elliott, Jonathan G Shaw, Craig V Comiter, Bertha Chen, Eric R Sokol.   

Abstract

PURPOSE: We compare the cost-effectiveness of 3 strategies for the use of a mid urethral sling to prevent occult stress urinary incontinence in patients undergoing abdominal sacrocolpopexy.
MATERIALS AND METHODS: Using decision analysis modeling we compared cost-effectiveness during a 1-year postoperative period of 3 treatment approaches including 1) abdominal sacrocolpopexy alone with deferred option for mid urethral sling, 2) abdominal sacrocolpopexy with universal concomitant mid urethral sling and 3) preoperative urodynamic study for selective mid urethral sling. Using published data we modeled probabilities of stress urinary incontinence after abdominal sacrocolpopexy with or without mid urethral sling, the predictive value of urodynamic study to detect occult stress urinary incontinence and the likelihood of complications after mid urethral sling. Costs were derived from Medicare 2010 reimbursement rates. The main outcome modeled was incremental cost-effectiveness ratio per quality adjusted life-years gained. In addition to base case analysis, 1-way sensitivity analyses were performed.
RESULTS: In our model, universally performing mid urethral sling at abdominal sacrocolpopexy was the most cost-effective approach with an incremental cost per quality adjusted life-year gained of $2,867 compared to abdominal sacrocolpopexy alone. Preoperative urodynamic study was more costly and less effective than universally performing intraoperative mid urethral sling. The cost-effectiveness of abdominal sacrocolpopexy plus mid urethral sling was robust to sensitivity analysis with a cost-effectiveness ratio consistently below $20,000 per quality adjusted life-year.
CONCLUSIONS: Universal concomitant mid urethral sling is the most cost-effective prophylaxis strategy for occult stress urinary incontinence in women undergoing abdominal sacrocolpopexy. The use of preoperative urodynamic study to guide mid urethral sling placement at abdominal sacrocolpopexy is not cost-effective.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ASC; ICER; MUS; QALY; SUI; UDS; abdominal sacrocolpopexy; costs and cost analysis; incremental cost-effectiveness ratio; mid urethral sling; pelvic organ prolapse; quality adjusted life-year; stress; stress urinary incontinence; suburethral slings; urinary incontinence; urodynamic study

Mesh:

Year:  2013        PMID: 23524201     DOI: 10.1016/j.juro.2013.03.046

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  Abdominal sacral colpopexy versus sacrospinous ligament fixation: a cost-effectiveness analysis.

Authors:  Mika S Ohno; Monica L Richardson; Eric R Sokol
Journal:  Int Urogynecol J       Date:  2015-08-19       Impact factor: 2.894

Review 2.  Stress incontinence surgery at the time of prolapse surgery: mandatory or forbidden?

Authors:  Ashley B King; Howard B Goldman
Journal:  World J Urol       Date:  2015-05-20       Impact factor: 4.226

3.  The negative predictive value of preoperative urodynamics for stress urinary incontinence following prolapse surgery.

Authors:  Tania Sierra; Gina Sullivan; Katherine Leung; Michael Flynn
Journal:  Int Urogynecol J       Date:  2019-01-14       Impact factor: 2.894

4.  Robotic-assisted Sacrocolpopexy with versus without Concomitant Midurethral Sling: A 2-year Follow-up of Urinary Symptoms and Quality of Life.

Authors:  Jeffrey S Schachar; Kathryn S Williams; Harvey A Winkler
Journal:  J Midlife Health       Date:  2018 Jan-Mar

5.  Heterogeneity of cost estimates in health economic evaluation research. A systematic review of stress urinary incontinence studies.

Authors:  Sandra Zwolsman; Arnoud Kastelein; Joost Daams; Jan-Paul Roovers; B C Opmeer
Journal:  Int Urogynecol J       Date:  2019-02-04       Impact factor: 2.894

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.